中文

华东医药 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-24
ItemAmountY/Y
Revenue¥11.18B+4.2%
Gross profit¥3.80B
Operating income¥1.20B
Net income¥1.00B+9.1%
Gross margin33.9%Net margin 8.9%
Revenue Q/Q+2.2%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥7.39B66.1%
R&D¥0.35B3.1%
SG&A¥2.19B19.6%
Tax & other¥0.20B1.8%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

山金国际浪潮信息华工科技华润三九中国铀业国货航招商公路招商蛇口新和成分众传媒思源电气紫光国微

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies